Further testing of alpelisib, which is FDA-approved for breast cancer treatment, and PF-04691502, currently in clinical trials, showed selective killing of CRC organoids harboring the RNF43_p.G659Vfs mutation (Fig. 3B). Here, RNF43 is linked to breast carcinoma.